Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-10
Adsett Roger Files Insmed (INSM) Form 4 - August 10, 2026
Adsett Roger traded 479.7K INSM shares worth $36.9M in this Form 4 filing, reported to the SEC on 2026-08-10.
- Insider
- Adsett Roger
- Issuer
- Insmed Inc. INSM · NASDAQ
- Filed
- Period
- 2026-08-10
- Accession
- 0001685904-26-000014
- Source
- Official filing on sec.gov ↗
Transactions (7)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Adsett Roger | 2026-08-10 | Buy | 82.3K | $13.67 | $1.1M | Direct |
| Adsett Roger | 2026-08-10 | Buy | 76.6K | $17.16 | $1.3M | Direct |
| Adsett Roger | 2026-08-10 | Buy | 81.0K | $30.46 | $2.5M | Direct |
| Adsett Roger | 2026-08-10 | Sell | 239.8K | $133.27 | $32.0M | Direct |
| Net change | 0 | −$27.1M | ||||
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Track INSM insider activity
Get alerted when Insmed Inc. executives buy or sell their shares.